More tools:Markets·Screener·Research·Chat

Arcus Biosciences, Inc. (RCUS) Financial Statements

Arcus Biosciences, Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00DQD2751
XNYS · usd
26.78▼ 1.71 (-6.00%)
As of 2026-09-10
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close28.49
Day's Range28.20 – 29.30
52-Week Range11.10 – 31.74
Volume1.8M
Avg Volume1.2M
Share Statistics
Shares Outstanding
Employees601
ExchangeXNYS
Listed2018-03-15
Share count as of July 30, 2026
Loading Income Statement…
Key questions about Arcus Biosciences, Inc. (RCUS)
What is Arcus Biosciences, Inc.'s Market Cap?
Arcus Biosciences, Inc.'s Market Cap is $3.4B, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s Enterprise Value?
Arcus Biosciences, Inc.'s Enterprise Value is $3.4B, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s Price / Sales?
Arcus Biosciences, Inc.'s Price / Sales is 29.1×, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s EV / Revenue?
Arcus Biosciences, Inc.'s EV / Revenue is 28.7×, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s EV / EBITDA?
Arcus Biosciences, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s Revenue (TTM)?
Arcus Biosciences, Inc.'s Revenue (TTM) is $117.0M, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s Net Income (TTM)?
Arcus Biosciences, Inc.'s Net Income (TTM) is -$460.0M, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s EBITDA?
Arcus Biosciences, Inc.'s EBITDA is -$476.0M, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s Diluted EPS (TTM)?
Arcus Biosciences, Inc.'s Diluted EPS (TTM) is -3.61, based on as-reported figures from SEC (XBRL) filings.
What is Arcus Biosciences, Inc.'s EBITDA Margin?
Arcus Biosciences, Inc.'s EBITDA Margin is -406.8%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth-74.4%-39.3%+26.9%-45.8%
Operating expenses:
Research and development (Includes $2, $11, $2 and $6 from a related party)
General and administrative (Includes $—, $2, $— and $2 from a related party)
Total operating expenses
% of revenue334.1%888.2%445.5%646.2%
Loss from operations
% of revenue-234.1%-788.2%-345.5%-546.2%
Non-operating income (expense):
Interest and other income, net
Interest expense
Total non-operating income, net
Income (loss) before income taxes
Income tax expense
Net income (loss)
% of revenue-222.0%-752.9%-321.2%-519.2%
Net income (loss) per share - basic (in dollars per share)
Net income (loss) per share - diluted (in dollars per share)